Inflammatix, a Burlingame, Calif.-based molecular diagnostics company delivering precision medicine at the point of care, raised $32m in Series C financing.
The round included participation from existing investors Khosla Ventures, Northpond Ventures and Think.Health Ventures, and new investors including Grey Sky Venture Partners.
The company intends to use the funds to advance its rapid HostDx™ tests through commercial launch in Europe and submission to the United States Food and Drug Administration in 2021.
Led by Tim Sweeney, M.D., Ph.D., cofounder and chief executive officer, Inflammatix is a molecular diagnostics company that is reimagining diagnostics by “reading” the patient’s immune system to deliver rapid results that improve care and reduce major public health burdens. The company’s initial focus is on acute infection and sepsis, where its HostDx™ tests combine proprietary biomarkers and advanced machine learning to help physicians quickly get the right treatments to the right patients. Each test will be developed to run on the company’s sample-to-answer isothermal instrument platform in under 30 minutes, enabling the power of precision medicine at the point of care.